WuXi Biologics Celebrates Triple Achievement of MSCI ESG Rating
WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully earned the prestigious AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This outstanding recognition demonstrates the company's unwavering dedication to environmental, social, and governance (ESG) excellence.
This top-tier rating by MSCI, known for being a leading global provider of ESG ratings and research, signifies that WuXi Biologics belongs to an elite group of companies acknowledged for their exceptional ESG performance. This honor underscores the company's ongoing commitment to championing sustainability, particularly in significant areas like climate change, product quality and safety, human capital development, and corporate governance.
MSCI's Extensive ESG Ratings Framework
MSCI ESG Ratings evaluate more than 17,000 issuers and around 999,000 securities worldwide. These evaluations provide crucial insights for investors, focusing on a company's ability to withstand industry-specific sustainability risks and seize related opportunities. It is this level of scrutiny and evaluation that makes the AAA rating such a noteworthy achievement for WuXi Biologics.
Dr. Chris Chen, the CEO of WuXi Biologics and Chair of the ESG Committee, expressed profound gratitude for this recognition. He stated, "We are deeply honored to receive an MSCI AAA rating for the third consecutive year, validating our persistent efforts in pursuing sustainability. As a global leader in Green CRDMO, we are committed to delivering ESG excellence and fostering partnerships that promote responsible practices across the industry."
Commitment to United Nations Goals
In alignment with the United Nations Sustainable Development Goals, WuXi Biologics actively engages with the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). The recent approval of the company’s new greenhouse gas emissions-reduction targets by the Science Based Targets initiative (SBTi) signals its ongoing commitment to sustainability and responsible environmental stewardship.
WuXi Biologics's proactive advocacy in sustainability has garnered widespread recognition. The company has achieved an EcoVadis Platinum Medal, earned spots on the Dow Jones Sustainability Indices, and secured a place in the CDP Water Security "A List". Additionally, it has been awarded an A- score for Climate Change leadership for two consecutive years, demonstrating its industry-leading commitment to sustainability strategies.
Further Recognition
WuXi Biologics has consistently received accolades for its ESG initiatives. Sustainalytics rated the company as having negligible risk and recognized it as a top-rated company in its industry for five consecutive years. Moreover, it has been selected as a constituent of the FTSE4Good Index Series and listed in the Hang Seng ESG 50 Index, receiving a Prime rating by ISS ESG Corporate Rating as well.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) stands out as a leading global CRDMO, providing end-to-end solutions that help partners navigate the entire process of discovering, developing, and manufacturing biologics. This comprehensive approach not only aims to benefit patients worldwide but also reinforces the company's position as a pioneer in the biologics industry.
With a workforce exceeding 12,000 skilled professionals across key regions, including the United States, Ireland, Germany, and Singapore, WuXi Biologics leverages advanced technologies to deliver cost-effective solutions throughout the biologics lifecycle. As of the recent count, the company supports over 864 integrated client projects, with 24 currently in commercial manufacturing.
WuXi Biologics considers sustainability vital to its long-term growth strategy. The company fosters green technology innovations, offering advanced Green CRDMO solutions. By prioritizing excellence in ESG, WuXi collaborates with stakeholders and clients to create shared value and promote practices that positively influence the global landscape.
Frequently Asked Questions
What is the significance of the MSCI AAA ESG rating?
The MSCI AAA ESG rating reflects a company's outstanding commitment to environmental, social, and governance practices, marking it as a leader in sustainability.
How many years has WuXi Biologics received the AAA rating?
WuXi Biologics has proudly achieved the MSCI AAA rating for three consecutive years, demonstrating consistent excellence in its ESG efforts.
What initiatives does WuXi Biologics engage in for sustainability?
WuXi Biologics actively aligns with the United Nations Sustainable Development Goals and collaborates with the UN Global Compact to drive sustainability initiatives.
What awards and recognitions has WuXi Biologics received for its ESG practices?
WuXi Biologics has received an EcoVadis Platinum Medal, been listed on the Dow Jones Sustainability Indices, and recognized by Sustainalytics among others for its commitment.
What is the role of Dr. Chris Chen in WuXi Biologics?
Dr. Chris Chen is the CEO and Chairman of the ESG Committee at WuXi Biologics, driving the company's initiatives towards sustainability and ESG leadership.
